Picture of Coherus Biosciences logo

CHRS Coherus Biosciences Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Annual cashflow statement for Coherus Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-238-20989.8132-287
Depreciation
Non-Cash Items39.736.649.251.1203
Unusual Items
Other Non-Cash Items
Changes in Working Capital-5.1310.3-114-32.142.9
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-200-15928.4154-37.4
Capital Expenditures-4.57-0.789-1.82-7.23-1.29
Purchase of Fixed Assets
Other Investing Cash Flow Items0.156-0.399-10.9-7.17-137
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-4.42-1.19-12.7-14.4-138
Financing Cash Flow Items-0.544-0.815-0.88-1.75
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities20710589.422451.9
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash1.96-54.6105364-124

Or unlock with your email

Or unlock with your email